| Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma BA Walker, EM Boyle, CP Wardell, A Murison, DB Begum, NM Dahir, ... Journal of clinical oncology 33 (33), 3911-3920, 2015 | 660 | 2015 |
| APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma BA Walker, CP Wardell, A Murison, EM Boyle, DB Begum, NM Dahir, ... Nature communications 6 (1), 6997, 2015 | 366 | 2015 |
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms BA Walker, CP Wardell, L Melchor, A Brioli, DC Johnson, MF Kaiser, ... Leukemia 28 (2), 384-390, 2014 | 351 | 2014 |
| Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t (4; 14) and t (11; 14) myeloma BA Walker, CP Wardell, L Melchor, S Hulkki, NE Potter, DC Johnson, ... Blood, The Journal of the American Society of Hematology 120 (5), 1077-1086, 2012 | 315 | 2012 |
| Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma L Melchor, A Brioli, CP Wardell, A Murison, NE Potter, MF Kaiser, ... Leukemia 28 (8), 1705-1715, 2014 | 288 | 2014 |
| Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma MF Kaiser, DC Johnson, P Wu, BA Walker, A Brioli, F Mirabella, ... Blood, The Journal of the American Society of Hematology 122 (2), 219-226, 2013 | 202 | 2013 |
| The complex genetic landscape of familial breast cancer L Melchor, J Benítez Human genetics 132, 845-863, 2013 | 200 | 2013 |
| The impact of intra‐clonal heterogeneity on the treatment of multiple myeloma A Brioli, L Melchor, M Cavo, GJ Morgan British journal of haematology 165 (4), 441-454, 2014 | 141 | 2014 |
| Wnt and Neuregulin1/ErbB signalling extends 3D culture of hormone responsive mammary organoids T Jardé, B Lloyd-Lewis, M Thomas, H Kendrick, L Melchor, L Bougaret, ... Nature communications 7 (1), 13207, 2016 | 117 | 2016 |
| Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes L Melchor, E Honrado, MJ Garcia, S Alvarez, J Palacios, A Osorio, ... Oncogene 27 (22), 3165-3175, 2008 | 111 | 2008 |
| Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes L Melchor, LP Saucedo-Cuevas, I Muñoz-Repeto, SM Rodríguez-Pinilla, ... Breast cancer research 11, 1-14, 2009 | 110 | 2009 |
| The spectrum and clinical impact of epigenetic modifier mutations in myeloma C Pawlyn, MF Kaiser, C Heuck, L Melchor, CP Wardell, A Murison, ... Clinical cancer research 22 (23), 5783-5794, 2016 | 109 | 2016 |
| Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations C Pawlyn, L Melchor, A Murison, CP Wardell, A Brioli, EM Boyle, ... Blood, The Journal of the American Society of Hematology 125 (5), 831-840, 2015 | 106 | 2015 |
| An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes L Melchor, J Benítez Carcinogenesis 29 (8), 1475-1482, 2008 | 94 | 2008 |
| A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation S Alvarez, R Diaz-Uriarte, A Osorio, A Barroso, L Melchor, MF Paz, ... Clinical Cancer Research 11 (3), 1146-1153, 2005 | 91 | 2005 |
| Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated … JR Jones, N Weinhold, C Ashby, BA Walker, C Wardell, C Pawlyn, ... Haematologica 104 (7), 1440, 2019 | 90 | 2019 |
| Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome A Brioli, H Giles, C Pawlyn, JP Campbell, MF Kaiser, L Melchor, ... Blood, The Journal of the American Society of Hematology 123 (22), 3414-3419, 2014 | 78 | 2014 |
| Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models L Melchor, G Molyneux, A Mackay, FA Magnay, M Atienza, H Kendrick, ... The Journal of pathology 233 (2), 124-137, 2014 | 61 | 2014 |
| Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families E Honrado, A Osorio, RL Milne, MF Paz, L Melchor, A Cascon, M Urioste, ... Modern Pathology 20 (12), 1298-1306, 2007 | 61 | 2007 |
| What is a science diplomat? L Melchor The Hague Journal of Diplomacy 15 (3), 409-423, 2020 | 55 | 2020 |
Brian A WalkerIndiana UniversityVerified email at iu.edu
